Background: The number of positive and death cases from coronavirus disease 2019 (COVID-19) is still increasing until now. One of the most prone individuals, even in normal situations is patients with HIV. Currently, the evidence regarding the link between HIV and COVID-19 is still limited and conflicting. This study aims to analyze the relationship between HIV and poor outcomes of COVID-19 infection. Methods: We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until January 12th, 2021. All articles published on COVID-19 and HIV were retrieved. The quality of the study was assessed using the Newcastle Ottawa Scale (NOS) tool for observational studies. Statistical analysis was done using Review Manager 5.4 and Comprehensive Meta-Analysis version 3 software. Results: A total of 38 studies with 18,271,025 COVID-19 patients were included in this meta-analysis. This meta-analysis showed that HIV was not associated with composite poor outcome [OR 1.08 (95% CI 0.95 – 1.23), p = 0.26, I2 = 68%, random-effect modelling]. Meta-regression showed that the association with composite poor outcome was influenced by hypertension (p < 0.00001) and diabetes (p = 0.0007). Subgroup analysis which involves only studies from African region showed that HIV was associated with composite poor outcomes [OR 1.11 (95% CI 1.03 – 1.21), p = 0.01, I2 = 0%, random-effect modelling]. Conclusions: Patients with HIV should still be considered as a population for whom precautions are needed to prevent the COVID-19. The availability of antiretroviral therapy should be ensured.

中文翻译：

---

人类免疫缺陷病毒（HIV）和2019年冠状病毒病（COVID-19）肺炎的结局：一项荟萃分析和荟萃回归

背景：到目前为止，2019年冠状病毒病（COVID-19）阳性和死亡病例的数量仍在增加。即使在正常情况下，艾滋病毒感染者也是最容易出现的个体之一。目前，有关艾滋病毒与COVID-19之间联系的证据仍然有限且相互矛盾。本研究旨在分析HIV与COVID-19感染不良预后之间的关系。方法：我们使用与我们的目标相关的特定关键字，系统搜索了PubMed和Europe PMC数据库，直到2021年1月12日。所有在COVID-19和HIV上发表的文章均被检索。研究质量使用纽卡斯尔渥太华量表（NOS）工具进行观察性研究评估。使用Review Manager 5.4和Comprehensive Meta-Analysis第三版软件进行统计分析。结果：共有38项研究，其中18项，该荟萃分析纳入了271,025名COVID-19患者。这项荟萃分析显示，HIV与综合不良结局无关[OR 1.08（95％CI 0.95 – 1.23），p = 0.26，I2 = 68％，随机效应模型]。荟萃回归显示，与综合不良结局的关系受高血压（p <0.00001）和糖尿病（p = 0.0007）的影响。仅涉及非洲地区研究的亚组分析表明，艾滋病毒与综合不良结局相关[OR 1.11（95％CI 1.03 – 1.21），p = 0.01，I2 = 0％，随机效应模型]。结论：HIV患者仍应被视为需要预防COVID-19的人群。应确保抗逆转录病毒疗法的可用性。这项荟萃分析显示，HIV与综合不良结局无关[OR 1.08（95％CI 0.95 – 1.23），p = 0.26，I2 = 68％，随机效应模型]。荟萃回归显示，与综合不良结局的关系受高血压（p <0.00001）和糖尿病（p = 0.0007）的影响。仅涉及非洲地区研究的亚组分析表明，艾滋病毒与综合不良结局相关[OR 1.11（95％CI 1.03 – 1.21），p = 0.01，I2 = 0％，随机效应模型]。结论：HIV患者仍应被视为需要预防COVID-19的人群。应确保抗逆转录病毒疗法的可用性。这项荟萃分析显示，HIV与综合不良结局无关[OR 1.08（95％CI 0.95 – 1.23），p = 0.26，I2 = 68％，随机效应模型]。荟萃回归显示，与综合不良结局的关系受高血压（p <0.00001）和糖尿病（p = 0.0007）的影响。仅涉及非洲地区研究的亚组分析表明，艾滋病毒与综合不良结局相关[OR 1.11（95％CI 1.03 – 1.21），p = 0.01，I2 = 0％，随机效应模型]。结论：HIV患者仍应被视为需要预防COVID-19的人群。应确保抗逆转录病毒疗法的可用性。荟萃回归显示，与综合不良结局的关系受高血压（p <0.00001）和糖尿病（p = 0.0007）的影响。仅涉及非洲地区研究的亚组分析表明，艾滋病毒与综合不良结局相关[OR 1.11（95％CI 1.03 – 1.21），p = 0.01，I2 = 0％，随机效应模型]。结论：HIV患者仍应被视为需要预防COVID-19的人群。应确保抗逆转录病毒疗法的可用性。荟萃回归显示，与综合不良结局的关系受高血压（p <0.00001）和糖尿病（p = 0.0007）的影响。仅涉及非洲地区研究的亚组分析表明，艾滋病毒与综合不良结局相关[OR 1.11（95％CI 1.03 – 1.21），p = 0.01，I2 = 0％，随机效应模型]。结论：HIV患者仍应被视为需要预防COVID-19的人群。应确保抗逆转录病毒疗法的可用性。结论：HIV患者仍应被视为需要预防COVID-19的人群。应确保抗逆转录病毒疗法的可用性。结论：HIV患者仍应被视为需要预防COVID-19的人群。应确保抗逆转录病毒疗法的可用性。